Previous 10 | Next 10 |
JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a late-clinical stage, leader in the development of orally delivered peptides and therapeutic proteins, today announced that the Company will participate in the SVB...
Entera Bio press release ( NASDAQ: ENTX ): Q3 GAAP EPS of -$0.11. As of September 30, 2022, Entera had cash and cash equivalents of $14.3 million, compared to $17.3 million as of June 30, 2022. Revenues for the three months ended September 30, 2022 were $8,000 compared...
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial results for the third quarter of 2022 and pro...
Entera Bio ( NASDAQ: ENTX ) said the U.S. Food and Drug Administration (FDA) agreed that a single Phase 3 placebo-controlled study could support a new drug application seeking approval of EB613 to treat post-menopausal women with osteoporosis. In the meeting ...
JERUSALEM, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced today the successful conclusion of its Type C meeting and agreeme...
JERUSALEM, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it will host a key opinion leader (KOL) webinar on t...
JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins , today announced that the Company will present and host 1x1 meetings a...
JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced the details of “A Six-month Phase 2 Study of Oral P...
Entera Bio press release ( NASDAQ: ENTX ): 1H GAAP EPS of -$0.24. Revenue of $0.11M (-59.3% Y/Y). Shares +3.68% PM For further details see: Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M
JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial and operating results for the quarter ended J...
News, Short Squeeze, Breakout and More Instantly...